Braxia Scientific Corp.

Braxia Scientific, headed by one of the world’s leading leading depression researchers, aims to treat people with depression and debilitating mental illnesses by revolutionizing global mental healthcare practices and developing the next generation of novel ketamine and psychedelic treatments, and delivery systems, through a growing network of Braxia clinics. Through the Braxia Institute, principals have launched various training programs to develop, train and support a new generation of qualified, skilled in best practices independent medical physicians, psychologists and psychotherapists to implement safe and effective ketamine and psilocybin-assisted therapy for patients with depression. BRAXIA = Brain + Ataraxia

Tryp Therapeutics

Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN™, program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders.

Cybin Inc.

We’re on a mission to revolutionize mental healthcare. Cybin is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Awakn Life Sciences

We are integrating psychedelic medicine into mainstream healthcare to enable better mental health for more people through Research, Clinics, and Ecosystems.

Gwella

Gwella makes mushrooms for modern life. Our mission is to build the most accessible and original over the counter portfolio of functional and psychedelic mushroom products that amplify individual and community wellness.